Managing Recurrences of Epithelial Ingrowth with Adhesive Assist

David R. Hardten, M.D. Minneapolis, Minnesota Have done research, consulting, or speaking for: Allergan, AMO, Calhoun Vision, CXL-USA, ESI, Humanoptics, Oculus, OSO, Ouantet, TLCV Some of the information may represent off-label uses of approved drugs or devices Construction of the information may represent off-label uses of approved drugs or devices Construction of the information may represent off-label uses of approved drugs or devices Construction of the information may represent off-label uses of approved drugs or devices Construction of the information may represent off-label uses of approved drugs or devices Construction of the information may represent off-label uses of approved drugs or devices Construction of the information may represent off-label uses of approved drugs or devices Construction of the information may represent off-label uses of approved drugs or devices Construction of the information may represent off-label uses of approved drugs or devices Construction of the information may represent off-label uses of approved drugs or devices Construction of the information may represent off-label uses of approved drugs or devices Construction of the information may represent off-label uses of approved drugs or devices Construction of the information may represent off-label uses of approved drugs or devices Construction of the information may represent off-label uses of approved drugs or devices Construction of the information may represent off-label uses of approved drugs or devices Construction of the information may represent off-label uses of approved drugs or devices Construction of the information may represent off-label uses of approved drugs or devices Construction of the information may represent off-label uses of approved drugs or devices Construction of the information may represent off-label uses of approved drugs or devices Construction of the information of the informa

Epithelial Ingrowth

Complication of LASIK surgery

- Incidence 0.5 to 15%
- Usually observed in first few weeks
- May be nonprogressive or progressive
 In most advanced stage may result in flap melt

MINNESOTA EYE CONSULTANTS, PA



D.R. Hardten, M.D.

Treatment - Removal

Removal

- Lifting and scraping epithelial cells
- Blunt spatula, Merocel sponge
- Ethanol used to supplement complete removal
- MMC has no role in management
- PTK to remove additional cells can induce significant irregular astigmatism
- Nd:YAG Laser treatment
- Useful for stable pockets of ingrowth where the elevation of the cornea causing changes in comfort or vision

D.R. Hardten, M.D

D.R. Hardten, M.D.

MINNESOTA EYE CONSULTANTS, PA

Treatment – Prevention of Recurrence

Prevention of Recurrence

- Suturing flap edges
 - Induce striae, irregular astigmatism, requires suture removal, longer recovery
- Fibrin adhesive application
- Useful for recurrent cases
- Longer recovery

MINNESOTA EYE CONSULTANTS, PA

Tisseel Fibrin Glue

Baxter (tissuesealing.com)

Mixture of:

- Fibrinogen & Thrombin
- Also has fibrinolysis inhibitor (bovine)
- Mixed on surface of the eye
- 30-60 seconds to manipulate it
- Thrombin can be diluted to slow the setting time
- 8-10 minutes to dry so BSCL can be placed
- Dissolves in 10-14 days

















Results in Study of 39 Eyes

```
      Hind Subset

      • ASIK surgery

      • Epithelial ingrow thecurred despite prior removal or enhancement

      • Bit Surgery

      • Following LASIK enhancement: 32 eyes

      • Silp PK and LASIK enhancement: 4 eyes

      • ShP RK and LASIK enhancement: 4 eyes

      • Owlows mak factors: 2 eyes

      • Person transmission

      • Up to 5 removals

      • Up to 5 removal attempts previously

      • Ownowa attempts previously

      • Ownowa attempts previously

      • Storeurence: 79.5%

      • 3 clinically significant recurrences requiring subsequent removal (7.7%)

      • Average 23.0 ± 19.1 months follow-up

      Hardten, et. AL, JCRS 2014, Combination of MEC & Duke University Eyes
```

Results

- Eyes with ≥ 3 months follow-up (3 to 66 months):
 Two eyes underwent flap amputation due to irregular astigmatism.
 - One eye had ectasia with subsequent Intacs placement
 - One eye had poor vision from glaucoma (2/200 to CF)
 - 92.3% had unchanged or improved BCVA
 - 5.1% lost one line of BCVA
- BCVA improved from 61% with 20/25 BCVA preop to 76% at 3 months postop and 84% at last follow-up.

D.R. Hardten, M.D.

D.R. Hardten, M.D.

MINNESOTA EYE CONSULTANTS, PA

Nd:YAG Laser

Epithelial Ingrowth Removal

Ayala, et. al.: AJO 2008;145:630.

- 0.6 mJ
- Variable number of spots depending on amount of ingrowth

•40% of cases required 2 or more sessions

MINNESOTA EYE CONSULTANTS, PA

Epithelial Ingrowth

Nd:YAG Laser

M

30 eyes Starting in the center of the ingrowth Average energy 0.6mJ FML TID 2 weeks postop Opacities resolve fully in 80% Mild opacity remained in 20%

Ayala, et. al.: AJO 2008;145:630



FIGURE 1. Photograph from Case 1 showing very dens epithelial ingrowth with bubbles in the area treated with neodymium:yytrium-aluminum-garnet (Nd:YAG) laser.

Page 6

Epithelial Ingrowth

Nd:YAG Laser



MINNESOTA EYE CONSULTANTS, PA

D.R. Hardten, M.D.

Conclusions

- Tisseel/Artiss may be a useful adjunct in epithelial ingrowth removal in complicated cases May reduce incidence of recurrent epi ingrowth
- Tisseel/Artiss is well tolerated and there were no complications associated with its use
- Larger randomized studies would be needed to determine safety and efficacy of this technique as compared to primary removal or sutures
- Nd:YAG may be useful for stable long-standing ingrowth destruction Hardten, et al., JCRS 2014, Anderson, et al.: JCRS 2003;29:1425 Ayala, et al.: AJO 2008;145:630 MINNESOTA EYE CONSULTANTS, FA D.R. Hardten, M.D.